Search
Oxibendazole
go.drugbank.com/drugs/DB04910ExperimentalVet approvedOxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
TA-CIN
go.drugbank.com/drugs/DB05809InvestigationalTA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
MUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalThe Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
alpha-Linolenic acid
go.drugbank.com/drugs/DB00132ApprovedInvestigationalNutraceuticalWithdrawnAlpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition.
Epoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
XL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation
Oregovomab
go.drugbank.com/drugs/DB04964InvestigationalOregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. … HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalKW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity